Enanta Pharmaceuticals Inc.

ENTA:NASDAQ

Enanta's research and development efforts are currently focused on the following disease targets: respiratory syncytial virus (RSV), non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), and hepatitis B virus (HBV).

streetwise book logo Streetwise Company Fact Sheet

2024/5/20 6:07:38

(ENTA:NASDAQ)

Streetwise Reports Articles

06/02/2022 - View Article